

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
51752-US-PCT  
APPLICATION NO.  
10/593,135  
APPLICANT  
ABLA CREASEY  
FILING DATE  
SEPTEMBER 18, 2006

Group

## U.S. PATENT DOCUMENTS

| EXAMINER INITIAL |    | DOCUMENT NUMBER | DATE     | NAME                 | CLASS | SUBCLASS | FILING DATE |
|------------------|----|-----------------|----------|----------------------|-------|----------|-------------|
|                  | AA | RE 36,476       | 12/28/99 | Khouri et al.        |       |          |             |
|                  | AB | 4,599,176       | 7/8/86   | Wittenberger         |       |          |             |
|                  | AC | 5,276,015       | 1/4/94   | Khouri et al.        |       |          |             |
|                  | AD | 5,736,364       | 4/7/98   | Kelley et al.        |       |          |             |
|                  | AE | 5,859,005       | 1/12/99  | Mohan et al.         |       |          |             |
|                  | AF | 5,874,407       | 2/23/99  | Kelley et al.        |       |          |             |
|                  | AG | 5,885,781       | 3/23/99  | Johnson et al.       |       |          |             |
|                  | AH | 5,888,968       | 3/30/99  | Chen et al.          |       |          |             |
|                  | AI | 5,902,582       | 5/11/99  | Hung                 |       |          |             |
|                  | AJ | 5,914,316       | 6/22/99  | Brown et al.         |       |          |             |
|                  | AK | 5,977,057       | 11/2/99  | Van't Veer et al.    |       |          |             |
|                  | AL | 5,981,471       | 11/9/99  | Papathanassis et al. |       |          |             |

## FOREIGN PATENT DOCUMENTS

|  |    | DOCUMENT NUMBER | DATE     | OFFICE | CLASS | SUBCLASS | TRANSLATION YES<br>NO  |
|--|----|-----------------|----------|--------|-------|----------|--|
|  | AM | WO 93/24143     | 12/9/93  | PCT    |       |          | <input type="checkbox"/> <input checked="" type="checkbox"/> |
|  | AN | WO 93/25230     | 12/23/93 | PCT    |       |          | <input type="checkbox"/> <input checked="" type="checkbox"/> |
|  | AO | WO 99/00418     | 1/7/99   | PCT    |       |          | <input type="checkbox"/> <input checked="" type="checkbox"/> |
|  | AP | WO 01/49315     | 7/12/01  | PCT    |       |          | <input type="checkbox"/> <input checked="" type="checkbox"/> |
|  | AQ | WO 01/60837     | 8/23/01  | PCT    |       |          | <input type="checkbox"/> <input checked="" type="checkbox"/> |

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

|    |  |
|----|--|
| AR | BAJAJ et al. "Tissue factor pathway inhibitor Expression by Human Pleural Mesothelial and Mesothelioma Cells", <i>Eur. Respir. J.</i> , Vol. 15, pp. 1069-1078 (2000).             |
| AS | DEHOUX et al., "Compartmentalized Cytokine Production within the Human Lung in Unilateral Pneumonia", <i>Am. J. Respir. Crit. Care Med.</i> , Vol. 150, pp. 710-716 (1994).        |
| AT | BOUTTEN et al., "Compartmentalized IL-8 and Elastase Release within the Human Lung in Unilateral Pneumonia", <i>Am. J. Respir. Crit. Care Med.</i> , Vol. 153, pp. 336-342 (1996). |

EXAMINER DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
51752-US-PCT  
APPLICATION NO.  
10/593,135  
APPLICANT  
ABLA CREASEY  
FILING DATE  
SEPTEMBER 18, 2006

Group

## U.S. PATENT DOCUMENTS

| EXAMINER INITIAL |    | DOCUMENT NUMBER | DATE     | NAME                | CLASS | SUBCLASS | FILING DATE |
|------------------|----|-----------------|----------|---------------------|-------|----------|-------------|
|                  | BA | 5,212,091       | 5/18/93  | Diaz-Collier et al. |       |          |             |
|                  | BB | 5,563,123       | 10/8/96  | Innis et al.        |       |          |             |
|                  | BC | 6,008,199       | 12/28/99 | Grinnell et al.     |       |          |             |
|                  | BD | 6,060,449       | 5/9/00   | Hamuro et al.       |       |          |             |
|                  | BE | 6,156,734       | 12/5/00  | Grinnell et al.     |       |          |             |
|                  | BF | 6,159,468       | 12/12/00 | Carlson et al.      |       |          |             |
|                  | BG | 6,180,607       | 1/30/01  | Davies et al.       |       |          |             |
|                  | BH | 6,238,878       | 5/29/01  | Jakobsen et al.     |       |          |             |
|                  | BI | 6,242,414       | 6/5/01   | Johnson et al.      |       |          |             |
|                  | BJ | 6,268,344       | 7/31/01  | Grinnell et al.     |       |          |             |
|                  | BK | 6,270,764       | 8/7/01   | Fisher et al.       |       |          |             |
|                  | BL | 6,294,648       | 9/25/01  | Delaria et al.      |       |          |             |

## FOREIGN PATENT DOCUMENTS

|  |    | DOCUMENT NUMBER | DATE    | OFFICE | CLASS | SUBCLASS | TRANSLATION YES<br><input type="checkbox"/> | NO<br><input type="checkbox"/> |
|--|----|-----------------|---------|--------|-------|----------|---|--------------------------------|
|  | BM | WO 03/032904    | 4/24/03 | PCT    |       |          | <input type="checkbox"/>                    | <input type="checkbox"/>       |
|  | BN | EP 268110 B1    | 5/25/88 | Europe |       |          | <input type="checkbox"/>                    | <input type="checkbox"/>       |
|  | BO | EP 270799 B1    | 6/15/88 | Europe |       |          | <input type="checkbox"/>                    | <input type="checkbox"/>       |
|  | BP | EP 318451 B1    | 5/31/89 | Europe |       |          | <input type="checkbox"/>                    | <input type="checkbox"/>       |
|  | BQ | EP 473564 A1    | 3/4/92  | Europe |       |          | <input type="checkbox"/>                    | <input type="checkbox"/>       |

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

|    |   |
|----|---|
| BR | DE MOERLOOSE et al., "Procoagulant activity in bronchoalveolar fluids" No relationship with tissue factor pathway inhibitor activity", <i>Thrombosis Research</i> , Vol. 65, pp. 507-518 (1992).  |
| BS | FELDMAN et al., "Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: Analysis of the mechanism of action predicts utility in other diseases", <i>Transplantation Proc.</i> , Vol. 30, No. 8, pp. 4126-4127 (December 1998). |
| BT | GÜNTHER et al. "Alveolar Fibrin Formation Caused by Enhanced Procoagulant and Depressed Fibrinolytic Capacities in Severe Pneumonia", <i>Am. J. Respir. Crit. Care Med.</i> , Vol. 161, pp 454-462 (2000).  |

EXAMINER \_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
51752-US-PCT  
APPLICATION NO.  
10/593,135  
APPLICANT  
ABA CREASEY  
FILING DATE  
SEPTEMBER 18, 2006

Group

## U.S. PATENT DOCUMENTS

| EXAMINER INITIAL |    | DOCUMENT NUMBER | DATE     | NAME                 | CLASS | SUBCLASS | FILING DATE |
|------------------|----|-----------------|----------|----------------------|-------|----------|-------------|
|                  | BA | 6,323,326       | 11/27/01 | Dorin et al.         |       |          |             |
|                  | BB | 6,344,197       | 2/5/02   | Fisher et al.        |       |          |             |
|                  | BC | 6,395,270       | 5/28/02  | Carlson et al.       |       |          |             |
|                  | BD | 6,444,434       | 9/3/02   | Jakobsen et al.      |       |          |             |
|                  | BE | 6,489,296       | 12/3/02  | Grinnell et al.      |       |          |             |
|                  | BF | 6,525,102       | 2/25/03  | Chen et al.          |       |          |             |
|                  | BG | 2001/0006806    | 7/5/01   | Fisher et al.        |       |          |             |
|                  | BH | 2001/0018204    | 8/30/01  | Papathanassis et al. |       |          |             |
|                  | BI | 2001/0028880    | 10/11/01 | Fisher et al.        |       |          |             |
|                  | BJ | 2001/0051154    | 12/13/01 | Roemisch et al.      |       |          |             |
|                  | BK | 2002/0006896    | 1/17/02  | Johnson et al.       |       |          |             |
|                  | BL | 2002/0006897    | 1/17/02  | Johnson et al.       |       |          |             |

## FOREIGN PATENT DOCUMENTS

|  |    | DOCUMENT NUMBER | DATE     | OFFICE | CLASS | SUBCLASS | TRANSLATION<br>YES       | TRANSLATION<br>NO        |
|--|----|-----------------|----------|--------|-------|----------|--------------------------|--------------------------|
|  | BM | EP 473564 B1    | 3/4/92   | Europe |       |          | <input type="checkbox"/> | <input type="checkbox"/> |
|  | BN | WO 85/04899     | 11/7/85  | PCT    |       |          | <input type="checkbox"/> | <input type="checkbox"/> |
|  | BO | WO 90/08158     | 7/26/90  | PCT    |       |          | <input type="checkbox"/> | <input type="checkbox"/> |
|  | BP | WO 91/02753     | 3/7/91   | PCT    |       |          | <input type="checkbox"/> | <input type="checkbox"/> |
|  | BQ | WO 91/19514     | 12/26/91 | PCT    |       |          | <input type="checkbox"/> | <input type="checkbox"/> |

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

|    |  |
|----|--|
| BR | SCHAAF et al., "Neutrophil Inflammation and Activation in Bronchiectasis: Comparison with Pneumonia and Idiopathic Pulmonary Fibrosis", <i>Respiration</i> , Vol. 67, pp. 52-59 (2000).                    |
| BS | VAN'T VEER et al., "Inhibitory Mechanism of the Protein C Pathway on Tissue Factor-induced Thrombin Generation", <i>The J. of Biological Chemistry</i> , Vol. 272, No. 12, pp. 2982-7994 (March 21, 1997). |
| BT | ABRAHAM, "Tissue Factor Inhibition and Clinical Trial Results of Tissue Factor Pathway Inhibitor in Sepsis", <i>Critical Care Medicine</i> , Vol. 28, No. 9, pp. S31-S33 (2000).                           |

EXAMINER \_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

(Use several sheets if necessary)

ATTY. DOCKET NO.  
51752-US-PCT  
APPLICATION NO.  
10/593,135  
APPLICANT  
ABLA CREESEY  
FILING DATE  
SEPTEMBER 18, 2006

Group

**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL |    | DOCUMENT NUMBER | DATE     | NAME              | CLASS | SUBCLASS | FILING DATE |
|------------------|----|-----------------|----------|-------------------|-------|----------|-------------|
|                  | BA | 2002/0032150    | 3/14/02  | Johnson et al.    |       |          |             |
|                  | BB | 2002/0137884    | 9/26/02  | Dorin et al.      |       |          |             |
|                  | BC | 2002/0177560    | 11/28/02 | Greenfield et al. |       |          |             |
|                  | BD | 2002/0177563    | 11/28/02 | Griffin et al.    |       |          |             |
|                  | BE | 2002/0197667    | 12/26/02 | Inis et al.       |       |          |             |
|                  | BF | 2002/0198138    | 12/26/02 | Macias            |       |          |             |
|                  | BG | 2003/0007966    | 1/9/03   | Hoffman et al.    |       |          |             |
|                  | BH | 2003/0022354    | 1/30/03  | Gerfitz et al.    |       |          |             |
|                  | BI | 2003/0073638    | 4/17/03  | Kjalke            |       |          |             |
|                  | BJ | 4,179,337       | 12/18/79 | Davis et al.      |       |          |             |
|                  | BK | 4,399,216       | 8/16/83  | Axel et al.       |       |          |             |
|                  | BL | 4,495,285       | 1/22/85  | Shimizu et al.    |       |          |             |

**FOREIGN PATENT DOCUMENTS**

|  |    | DOCUMENT NUMBER | DATE     | OFFICE | CLASS | SUBCLASS | TRANSLATION<br>YES<br>NO                                     |
|--|----|-----------------|----------|--------|-------|----------|--|
|  | BM | WO 92/06711     | 4/30/92  | PCT    |       |          | <input type="checkbox"/> <input checked="" type="checkbox"/> |
|  | BN | WO 92/07584     | 5/14/92  | PCT    |       |          | <input type="checkbox"/> <input checked="" type="checkbox"/> |
|  | BO | WO 93/25230     | 12/23/93 | PCT    |       |          | <input type="checkbox"/> <input checked="" type="checkbox"/> |
|  | BP | WO 00/77254     | 12-2000  | PCT    |       |          | <input type="checkbox"/> <input checked="" type="checkbox"/> |
|  | BQ | WO 96/40784     | 12/19/96 | PCT    |       |          | <input type="checkbox"/> <input checked="" type="checkbox"/> |

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

|    |  |
|----|--|
| BR | ABRAHAM, "Coagulation Abnormalities in Acute Lung Injury and Sepsis", <i>Am. J. Respir. Cell Mol. Biol.</i> , Vol. 22, No. 4, pp. 401-404 (April 2000).  |
| BS | ABRAHAM et al., "Efficacy and Safety of Titacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis; A Randomized Controlled Trial", <i>JAMA</i> , Vol. 290, No. 2, pp. 238-247, American Medical Association (July 9, 2003). |
| BT | ALBAN et al., "Plasma Levels of Total and Free Tissue Factor Pathway Inhibitor (TFPI) as Individual Pharmacological Parameters of Various Heparins", <i>Thromb. Haemost.</i> , Vol. 85, No. 5, pp. 824-829 (May 2001).                     |

**EXAMINER** \_\_\_\_\_ **DATE CONSIDERED** \_\_\_\_\_

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

.FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
51752-US-PCT  
APPLICATION NO.  
10/593,135  
APPLICANT  
ABA CREASEY  
FILING DATE  
SEPTEMBER 18, 2006

Group

## U.S. PATENT DOCUMENTS

| EXAMINER INITIAL |    | DOCUMENT NUMBER | DATE    | NAME           | CLASS | SUBCLASS | FILING DATE |
|------------------|----|-----------------|---------|----------------|-------|----------|-------------|
|                  | BA | 4,511,502       | 4/16/85 | Builder et al. |       |          |             |
|                  | BB | 4,530,787       | 7/23/85 | Shaked et al.  |       |          |             |
|                  | BC | 4,569,790       | 2/11/88 | Koths et al.   |       |          |             |
|                  | BD | 4,572,798       | 2/25/86 | Koths et al.   |       |          |             |
|                  | BE | 4,603,106       | 7/29/86 | Carami et al.  |       |          |             |
|                  | BF | 4,609,546       | 9/2/88  | Hiratani       |       |          |             |
|                  | BG | 4,620,948       | 11/4/88 | Builder et al. |       |          |             |
|                  | BH | 4,683,195       | 7/28/87 | Mullis et al.  |       |          |             |
|                  | BI | 4,683,202       | 7/28/87 | Mullis et al.  |       |          |             |
|                  | BJ | 4,711,845       | 12/8/87 | Gelfand et al. |       |          |             |
|                  | BK | 4,748,234       | 5/31/88 | Dorin et al.   |       |          |             |
|                  | BL | 4,766,106       | 8/23/88 | Katre et al.   |       |          |             |

## FOREIGN PATENT DOCUMENTS

|  |    | DOCUMENT NUMBER | DATE | OFFICE | CLASS | SUBCLASS | TRANSLATION YES<br>NO                             |
|--|----|-----------------|------|--------|-------|----------|---|
|  | BM |                 |      |        |       |          | <input type="checkbox"/> <input type="checkbox"/> |
|  | BN |                 |      |        |       |          | <input type="checkbox"/> <input type="checkbox"/> |
|  | BO |                 |      |        |       |          | <input type="checkbox"/> <input type="checkbox"/> |
|  | BP |                 |      |        |       |          | <input type="checkbox"/> <input type="checkbox"/> |
|  | BQ |                 |      |        |       |          | <input type="checkbox"/> <input type="checkbox"/> |

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

|    |  |
|----|--|
| BR | AMERI et al., "Expression of Tissue Factor Pathway Inhibitor by Cultured Endothelial Cells in Response to Inflammatory Mediators", <i>Blood</i> , Vol. 79, pp. 3219-3226 (1992).                       |
| BS | ANGUS et al., Unraveling Severe Sepsis: Why did OPTIMIST Fall and What's Next?", <i>JAMA</i> , Vol. 290, No. 2, pp. 256-258, "American Medical Association (July 9, 2003).                             |
| BT | BADIMON, "Potential Therapeutic Indications for Tissue Factor Inhibition", The IBC International Symposium on Advances in Anti-coagulant, Anti-thrombotic and Thrombolytic Drugs (September 11, 1998). |

EXAMINER DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
51752-US-PCT  
APPLICATION NO.  
10/593,135  
APPLICANT  
ABLA CREASEY  
FILING DATE  
SEPTEMBER 18, 2006

Group

**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL |    | DOCUMENT NUMBER | DATE     | NAME              | CLASS | SUBCLASS | FILING DATE |
|------------------|----|-----------------|----------|-------------------|-------|----------|-------------|
|                  | BA | 4,847,201       | 7/11/89  | Kawasaki et al.   |       |          |             |
|                  | BB | 4,929,700       | 5/29/90  | Halenbeck et al.  |       |          |             |
|                  | BC | 4,968,852       | 10/30/90 | Wun et al.        |       |          |             |
|                  | BD | 5,106,833       | 4/21/92  | Broze et al.      |       |          |             |
|                  | BE | 5,110,730       | 5/5/92   | Edgington et al.  |       |          |             |
|                  | BF | 5,219,994       | 6/15/93  | Buonassisi et al. |       |          |             |
|                  | BG | 5,223,427       | 6/29/93  | Edgington et al.  |       |          |             |
|                  | BH | 6,063,764       | 5/16/00  | Creasey et al.    |       |          |             |
|                  | BI | 6,824,997       | 11/2004  | Moore et al.      |       |          |             |
|                  | BJ | 6,660,852       | 12/2003  | Keshi et al.      |       |          |             |
|                  | BK | 6,011,136       | 1/4/00   | Dreyfuss et al.   |       |          |             |
|                  | BL |                 |          |                   |       |          |             |

**FOREIGN PATENT DOCUMENTS**

|  |    | DOCUMENT NUMBER | DATE | OFFICE | CLASS | SUBCLASS | TRANSLATION YES<br>NO  |
|--|----|-----------------|------|--------|-------|----------|--|
|  | BM |                 |      |        |       |          | <input type="checkbox"/> <input checked="" type="checkbox"/> |
|  | BN |                 |      |        |       |          | <input type="checkbox"/> <input checked="" type="checkbox"/> |
|  | BO |                 |      |        |       |          | <input type="checkbox"/> <input checked="" type="checkbox"/> |
|  | BP |                 |      |        |       |          | <input type="checkbox"/> <input checked="" type="checkbox"/> |
|  | BQ |                 |      |        |       |          | <input type="checkbox"/> <input checked="" type="checkbox"/> |

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

|    |   |
|----|---|
| BR | BAILEY et al. "Methylmercury as a Reversible Denaturing Agent for Agarose Gel Electrophoresis", <i>Anal. Bioch.</i> , Vol. 70, pp. 75-85 (1976).  |
| BS | BAJAJ et al., "Cultured Normal Human Hepatocytes do not Synthesize Lipoprotein-Associated Coagulation Inhibitor: Evidence that Endothelium is the Principal Site of Its Synthesis", <i>PNAS (USA)</i> , Vol. 87, pp. 8869-8873 (1990).                |
| BT | BAJAJ et al., Inhibitor of the Factor Vita-Tissue Factor complex is Reduced in Patients with Disseminated Intravascular Coagulation but not in Patients with Severe Hepatocellular Disease", <i>J. Clin. Invest.</i> , Vol. 79, pp. 1874-1878 (1987). |

**EXAMINER** **DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

(Use several sheets if necessary)

ATTY. DOCKET NO.  
51752-US-PCT  
APPLICATION NO.  
10/593,135  
APPLICANT  
ABLA CREASEY  
FILING DATE  
SEPTEMBER 18, 2006

Group

EXAMINER  
INITIAL**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

|  |    |   |
|--|----|---|
|  | DA | BEVILACQUA et al., "Recombinant Rumor Necrosis Factor Induces Procoagulant Activity in Cultured Human Vascular Endothelium: Characterization and Comparison with the Actions of Interleukin 1", <i>PNAS (USA)</i> , Vol. 83, pp. 4533-4537 (1986).  |
|  | DB | BOLIVAR et al., "Construction and Characterization of New Cloning Vehicles", <i>Gene</i> , Vol 2, pp. 95-113 (1977).  |
|  | DC | BONE et al. "Definitions for Sepsis and Organ Failure and guidelines for the Use of Innovative Therapies in Sepsis", <i>Chest.</i> , Vol. 101, pp. 1644-1655 (1992).  |
|  | DD | BOOSMAN et al., "Nontraditional Method Used to Determine The Disulfide Bonds of Human Tissue Factor Pathway Inhibitor from E. Coli", 11 <sup>th</sup> International conference on Methods in Protein Structure Analysis (September 5, 1998).  |
|  | DE | BRAECKMAN et al., "Population PK/PD Modeling and Computer assisted Trial Design (CATD) in Clinical Drug Development – A Case Example, 8 <sup>th</sup> Annual Workshop on Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis at Marina del Ray, CA (June 25-26, 1999). |
|  | DF | BROACH, "Construction of High Copy Yeast Vectors Using 2-μm Circle Sequences", <i>Methods in Enzymology</i> , Vol. 101, pp. 307-325 (1983).   |
|  | DG | BROACH et al., "Transformation in Yeast Development of a Hybrid Cloning Vector and Isolation of the CANI Gene", <i>Gene</i> , Vol. 8, pp. 121-133 (1979).   |
|  | DH | BROZE et al., "Regulation of Coagulation by a Multivalent Kunitz-Type Inhibitor", <i>Biochemistry</i> , Vol. 29, pp. 7539-7546 (1990).  |
|  | DI | BROZE et al., "The Lipoprotein-Associated Coagulation Inhibitor that inhibits the Factor VII-Tissue Factor Complex Also Inhibits Factor Xa: Insight Into its Possible Mechanism of Action", <i>Blood</i> , Vol. 71, pp. 335-343 (1988).   |
|  | DJ | BROZE et al., "Isolation of the Tissue Factor Inhibitor Produced by HepG2 Hepatoma Cells", <i>PNAS (USA)</i> , Vol. 84, pp. 1886-1890 (1987).   |
|  | DK | BROZNA, "Cellular Regulation of Tissue Factor", <i>Blood Coagulation Fibrinolysis</i> , Vol. 1, pp. 415-426 (1990).   |
|  | DL | CALLANDER et al., "Mechanisms of Binding of Recombinant Extrinsic Pathway Inhibitor (rEPI) to Cultured Cell Surfaces", <i>The Journal of Biological Chemistry</i> , Vol. 267, pp. 876-882 (1992).   |
|  | DM | CAMEROTA et al., "Delayed Treatment with Recombinant Human Tissue Factor Pathway Inhibitor Improves Survival in Rabbits with Gram-Negative Paritonitis", <i>J. Infect. Dis.</i> , Vol. 177, No. 3, pp. 668-76 (March 1998).   |
|  | DN | CLARKE et al., "Electron Procedure for Isolation of Centromere DNAs from <i>Saccharomyces Cerevisiae</i> ", <i>Meth. Enzymol.</i> , Vol. 101, pp. 300-325 (1983).   |

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
51752-US-PCT  
APPLICATION NO.  
10/593,135  
APPLICANT  
ABLA CREASEY  
FILING DATE  
SEPTEMBER 18, 2006

Group

EXAMINER  
INITIAL**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

|  |    |  |
|--|----|--|
|  | DA | CLEWELL et al. "Nature of Col E <sub>1</sub> , Plasmid Replication in Escherichia coli in the Presence of Chloramphenicol", <i>J. Bacteriol.</i> , Vol. 110, pp. 667-676 (1972)                                    |
|  | DB | CLEWELL et al., "Supercoiled Circular DNA-Protein Complex in Escherichia Coli: Purification and Induced Conversion to an Open Circular DNA Form", <i>PNAS (USA)</i> , Vol. 62, pp. 1159-1166 (1969)                |
|  | DC | COHEN et al., "Nonchromosomal Antibiotic Resistance in Bacteria: Genetic Transformation of Escherichia Coli by R-Factor DNA", <i>PNAS (USA)</i> , Vol. 69, pp. 2110-2114 (1972).                                   |
|  | DD | COLUCCI et al., "Cultured Human Endothelial Cells Generate Tissue Factor in Response to Endotoxin", <i>J. Clin. Invest.</i> , Vol. 71, pp. 1893-1896 (1983).   |
|  | DE | CORRIGAN, "Heparin Therapy in Bacterial Septicemia", <i>J. Pediatrics.</i> , Vol. 91, pp. 695-700 (1977).  |
|  | DF | CORRIGAN et al., "Heparin Therapy in Septicemia with Disseminated Intravascular Coagulation. Effect on Mortality and on Correction of Hemostatic Defects", <i>N. Engl. J. Med.</i> , Vol. 283, pp. 778-782 (1970). |
|  | DG | CREASEY, "New Potential Therapeutic Modalities: Tissue Factor Pathway Inhibitor", <i>Sepsis.</i> , Vol. 3, pp. 173-182 (1999).   |
|  | DH | CREASEY et al., "Tissue Factor Pathway Inhibitor Activity in Severe Sepsis", <i>Crit. Care Med.</i> , Vol. 29(7 Suppl.): pp. S126-S129 (2001).   |
|  | DI | CREASEY, "TFPI Biology and Pharmacology", IBC 9 <sup>th</sup> Annual Conference on Sepsis, Endotoxemia & Related Disorders (January 20, 1999).   |
|  | DJ | CREASEY, "Investigation of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis", ICAAC Meeting (September 26, 1999).  |
|  | DK | CREASEY, "Investigation of Tifacogin (rTFPI) for Severe Sepsis", Crit. Care Med. (October 28, 1999).   |
|  | DL | CREASEY, "Investigation of Tifacogin (rTFPI) for Severe Sepsis", 5 <sup>th</sup> World Congress on Trauma, Shock, Inflammation and Sepsis (November 30, 1999)  |
|  | DM | CREASEY et al., "Tissue Factor Pathway Inhibitor Reduces Mortality from Escherichia Coli Septic Shock", <i>J. Clin. Invest.</i> , Vol. 91 pp. 2850-2869 (June 1993).   |
|  | DN | CREASEY et al., "Endotoxin and Cytokine Profile in Plasma of Baboons Challenged with Lethal and Sublethal Escherichia coli", <i>Circ. Shock</i> , Vol. 33, pp. 84-91 (1991).                                       |

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
51752-US-PCT  
APPLICATION NO.  
10/593,135  
APPLICANT  
ABLA CREASEY  
FILING DATE  
SEPTEMBER 18, 2006

Group

EXAMINER  
INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

|  |    |   |
|--|----|---|
|  | DA | CROSS et al., "Choice of Bacteria in Animal Models of Sepsis", <i>Infect. Immun.</i> , Vol. 61, pp. 2741-2747 (1993).   |
|  | DB | DAY et al., "Recombinant Lipoprotein-Associated Coagulation Inhibitor Inhibits Tissue Thromboplastin-Induced Intravascular Coagulation in the Rabbit". <i>Blood</i> , 76, No. 8, pp. 1538-1545 (October 15, 1990).  |
|  | DC | DEJONGE et al., "Tissue Factor Pathway Inhibitor Dose-Dependently Inhibits Coagulation Activation without Influencing the Fibrinolytic and Cytokine Response During Human Endotoxemia", <i>Blood</i> , Vol. 95, No. 4, pp. 1124-1129 (February 15, 2000). |
|  | DD | DEJONGE et al., "Tissue Factor Pathway Inhibitor Does Not Influence Inflammatory Pathway During Human Endotoxemia", <i>J. Infect. Dis.</i> , Vol. 183, No. 12, pp. 1815-1818 (June 2001).   |
|  | DE | DEPICKER et al., "Nopaline Synthase: Transcript Mapping and DNA Sequence", <i>J. Mol. Appl. Gen.</i> , Vol. 1- pp. 561-573 (1982).  |
|  | DF | DHAINAUT et al., "Combined Procoagulant and Innate Immune Response to Infection: Toward More Potent Drugs in Septic Patients", <i>Crit. Care Med.</i> , Vol. 29, No. 1, pp. 205-207 (January 2001).   |
|  | DG | FIERS et al., "Complete Nucleotide sequence of SV40 DNA", <i>Nature</i> , Vol. 273, pp. 113-120 (1978).   |
|  | DH | FINK et al., "Laboratory Models of Sepsis and Septic Shock", <i>Journal of Surgical Research</i> , Vol. 49, pp. 186-196 (1990)  |
|  | DI | FISCHER et al., "Interleukin-Receptor Blockade Improves Survival Hemodynamic Performance in <i>Escherichia Coli</i> Septic Shock, but Fails to Alter Host Responses to Sublethal Endotoxemia", <i>J. Clin. Invest.</i> , Vol. 89, pp. 1551-1557 (1992).   |
|  | DJ | GIRARD et al., "Truncated Tissue Factor Pathway Inhibitor Protects Baboons from Lethal Doses of <i>E. Coli</i> ", <i>Blood, Coagulation &amp; Fibrinolysis</i> (2000).  |
|  | DK | GIRARD et al., "Identification of the 1.4 KB and 4.0 KB Messages for the Lipoprotein Associated Coagulation Inhibitor and Expression of the Encoded Protein", <i>Thrombosis Research</i> , Vol. 55, pp. 37-50 (1989).                                     |
|  | DL | GIRARD et al. "Functional Significance of the Kunitz-type Inhibitory Domains of Lipoprotein-Associated Coagulation Inhibitor", <i>Nature</i> , Vol. 338, pp. 518-520 (1989).  |
|  | DM | GOEDDEL et al., "Synthesis of Human Fibroblast Interferon by <i>E. coli</i> ". <i>Nuci. Acids Res.</i> , Vol. 8, pp. 4057-4074 (1980).  |
|  | DN | GRAHAM et al., "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA", <i>Virology</i> , Vol. 52, pp. 456-467 (1973).   |

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
51752-US-PCT  
APPLICATION NO.  
10/593,135  
APPLICANT  
ABLA CREASEY  
FILING DATE  
SEPTEMBER 18, 2006

Group

EXAMINER  
INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

|  |    |   |
|--|----|---|
|  | DA | HALL et al., "The Association of TFPI with Artificial Surfaces", 6 <sup>th</sup> World Biomaterials Congress.   |
|  | DB | HAMAMOTO et al., "Inhibitory Properties of Full-length and Truncated Recombinant Tissue Factor Pathway Inhibitor (TFPI)", <i>J. Biol. Chem.</i> , Vol. 268, pp. 8704-8710 (1993).   |
|  | DC | HASKEL et al., "Prevention Arterial Reocclusion After Thrombolysis With Recombinant Lipoprotein-Associated Coagulation Inhibitor", <i>Circulation</i> , Vol. 84, pp. 821-827 (1991)   |
|  | DD | HESS et al., "Cooperation of Glycolytic Enzymes", <i>J. Adv. Enzyme Reg.</i> , Vol. 7, pp. 149-167 (1968).  |
|  | DE | HINSHAW, et al., "Survival of Primates in LD <sub>100</sub> Septic Shock Following Steroid/Antibiotic Therapy", <i>J. Surg. Res.</i> , Vol. 28, pp. 151-170 (1989).   |
|  | DF | HINSHAW et al., "Detection of the 'Hyperdynamic State' Sepsis in the Baboon During Lethal E. coli Infusion", <i>J. Trauma</i> , Vol. 23, pp. 361-365 (1983).  |
|  | DG | HINSHAW et al., "Survival of Primates in LD <sub>100</sub> Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNFa)", <i>Circulatory Shock</i> , Vol. 30, pp. 279-292 (1990).                                   |
|  | DH | HITZEMAN et al., "Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique", <i>J. Biol. Chem.</i> , Vol. 255, pp. 12073-12080 (1980)                                  |
|  | DI | HOLLAND et al., "The Primary Structures of Two Yeast Enolase Gene", <i>J. Biol. Chem.</i> , Vol. 256, pp. 1385-1395 (1981).   |
|  | DJ | HOLLAND et al., "Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase", <i>Biochemistry</i> , Vol. 17, pp. 4900-4907 (1978). |
|  | DK | HOLST et al., "Antithrombotic Properties of a Truncated Recombinant Tissue Factor Pathway Inhibitor in an Experimental Venous Thrombosis Model", <i>Haemostasis</i> , Vol. 23(suppl. 1), pp. 112-117 (1993).                        |
|  | DL | HSIAO et al., "High-Frequency Transformation of Yeast by Plasmids Containing the Cloned Yeast ARGA Gene", <i>PNAS (USA)</i> , Vol. 76, pp. 3829-3833 (1979).  |
|  | DM | KAUS, "Pharmacokinetics and Pharmacodynamics of Recombinant Tissue Factor Pathway Inhibitor (r-TFPI)" Effect of IV and SC Heparin Administration", AAPS Annual Meeting (October 29, 1999).  |
|  | DN | KEMME et al., "The Influence of Reduced Liver Blood Flow (LBF) on the Pharmacokinetics (PK) of Recombinant Tissue Factor Pathway Inhibitor (rTFPI)", 1999 Amerian Society for Clinical Pharmacology Therapeutics Meeting.           |

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
S1752-US-PCT  
APPLICATION NO.  
10/593,135  
APPLICANT  
ABLA CREASEY  
FILING DATE  
SEPTEMBER 18, 2006

Group

EXAMINER  
INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

|  |    |   |
|--|----|---|
|  | DA | KNAUF et al., "Relationship of Effective Molecular size to Systemic Clearance in Rats of Recombinant Interleukin-2 Chemically Modified with Water-Soluble Polymers", <i>J. Biol. Chem.</i> , Vol. 263, pp. 15064-15070 (1988).                                      |
|  | DB | KRISTENSEN et al., Effect of Tissue Factor Pathway Inhibitor (TFPI) in the HEPTEST® Assay and in an Amidolytic Anti Factor Xa Assay for LMW Heparin", <i>Thrombosis Flämost</i> , CF.K. Schattauer Verlagsgesellschaft mbH (Stuttgart) Vol. 68, pp. 310-314 (1992). |
|  | DC | KUNKEL et al., "Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection", <i>Proc. Nat. Acad. Sci. USA</i> , Vol. 82-488-492 (1985).   |
|  | DD | LASCH et al., "Heparin Therapy of Diffuse Intravascular Coagulation 9DEC", <i>Thrombos. Diathes. Haemorrh. (Stuttg.)</i> , Vol. 33, pp. 105-106 (1974).   |
|  | DE | LEE et al., "Coagulation Inhibitors in Sepsis and Disseminated Intravascular Coagulation", <i>Intensive Care Med.</i> , Vol. 26, No. 11, pp. 1701-1706 (November 2000).   |
|  | DF | LEIGHTON, 'Tissue Factor Pathway Inhibitor biology and Pharmacology", ISTH (August 14, 1999).   |
|  | DG | LEVI et al., "Novel Approaches to the Management of Disseminated Intravascular Coagulation", <i>Crit. Care Med.</i> , Vol. 28, No. 9(suppl.) pp. 520-4 (September 2000).  |
|  | DH | LINDHOUT et al., "Activation of Factor X and Its Regulation by Tissue Factor Pathway Inhibitor in Small-Diameter Capillaries Lined With Human Endothelial Cells", <i>Blood</i> , Vol. 79, pp. 2909-2016 (1992).   |
|  | DI | LYBERG et al., "Cellular Cooperation in Endothelial Cell Thromboplastin Synthesis", <i>British Journal of Haematology</i> , Vol. 53, pp. 85-95 (1983).  |
|  | DJ | MANIATAS et al., Molecular Cloning – A Laboratory Manual, Cold Spring Harbor Press, p. 202-203 (1982).  |
|  | DK | MARTIN et al., "Prospective National Study of Gram-Negative Bacterial (GNB) Sepsis – Natural History in the 1980s", Abstract No. 317, 29 <sup>th</sup> ICAAC Meeting, Houston (1989).   |
|  | DL | MATTEUCCI et al., "Synthesis of Deoxyoligonucleotides on a Polymer Support", <i>J. Am. Chem. Soc.</i> , Vol. 103, pp. 3185-3191 (1981).   |
|  | DM | MATTYAL et al., "Extremely Low Doses of TFPI Decrease Mortality in a Rabbit Model of Septic Shock", <i>Intensive Care Med.</i> , 27(8):1274-1280 (August 2001).   |
|  | DN | MAXAM et al., "Sequencing End-labeled DNA with Base-Specific Chemical Cleavages.", <i>Math. Enzymol.</i> , Vol. 65, pp. 499-560 (1980).   |

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

(Use several sheets if necessary)

ATTY. DOCKET NO.  
51752-US-PCT  
APPLICATION NO.  
10/593,135  
APPLICANT  
ABLA CREASEY  
FILING DATE  
SEPTEMBER 18, 2006

Group

EXAMINER  
INITIAL**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

|    |   |
|----|---|
| DA | MESSING et al., "A System for Shotgun DNA Sequencing., <i>Nucl Acids Res.</i> , Vol. 9 pp. 309-321 (1981)   |
| DB | MMWR, <i>Septicemia</i> , Vol. 39, No. 2, pp. 31-34 (1987).   |
| DC | MMWR, <i>Hospitalizations</i> , Vol. 39, No. 43 pp. 777-785 (1987)  |
| DD | MÜLLER-BERGHAUS, "Pathophysiologic and Biochemical Events in Disseminated Intervascular Coagulation; Dysregulate of Procoagulant Anticoagulant Pathways", <i>Seminars in Thrombosis and Haemostasis</i> , Vol. 15 pp. 58-87 (1989).                         |
| DE | NAWROTH et al., "Interleukin 1 Induces Endothelial Cell Procoagulant While Suppressing Cell-Surface Anticoagulant Activity", <i>PNAS (USA)</i> , Vol. 83 pp. 3460-3464 (1986).  |
| DF | NEMERSON, "Tissue Factor and Hemostasis", <i>Blood</i> , Vol. 71 pp. 1-8 (1988).  |
| DG | NOVOTNY et al., "Purification and Properties of Heparin-Releasable Lipoprotein-Associated Coagulation Inhibitor", <i>Blood</i> , Vol. 78, pp. 394-400 (1991).   |
| DH | NOVOTNY et al., "Purification and Characterization of the Lipoprotein-Associate Coagulation Inhibitor from Human Plasma", <i>J. Biol. Chem.</i> , Vol. 264:18832-18837 (1989).  |
| DJ | NORDFANG et al., "Inhibition of Extrinsic Pathway Inhibitor Shortens the Coagulation Time of Normal Plasma and of Hemophilia Plasma", <i>Thrombosis and Haemostasis</i> , F.K. Schattauer Verlagsgesellschaft mbH (Stuttgart), Vol. 66, pp. 464-467 (1991). |
| DK | NORDFANG et al., "The C-Terminus of Tissue Factor Pathway Inhibitor is Essential to Its Anticoagulant Activity", <i>Biochemistry</i> , Vol. 30, pp.10371-10376 (1991).  |
| DL | OBUKOWICZ et al., "Secretion of Active Kringle-2-Serine Protease In <i>Escherichia coli</i> ", <i>Biochemistry</i> , Vol. 29, pp. 9737-9745 (1990).   |
| DM | OLINS et al., "A Novel Sequence Element Derived from Bacteriophage T7 mRNA Acts as <i>Escherichia coli</i> ", <i>Journal of Biological Chemistry</i> , Vol. 264, pp.16973-16976 (1989).   |
| DN | Opal et al., "The Activity of Tissue Factor Pathway Inhibitor (TFPI) in Experimental Models of Superantigen-Induced and Polymicrobial Sepsis", <i>ICMC</i> , April 27, 1999, Abstract Only  |

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
51752-US-PCT  
APPLICATION NO.  
10/593,135  
APPLICANT  
ABLA CREASEY  
FILING DATE  
SEPTEMBER 18, 2006

Group

EXAMINER  
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

|  |    |   |
|--|----|---|
|  | DA | OSTERGAARD et al., <i>Haemostasis</i> , Vol. 23(suppl. 1), pp. 107-111 (1993).  |
|  | DB | OSTERUD et al., "Increased Tissue Thromboplastin Activity in Monocytes of Patients with Meningococcal Infection: Related to an Unfavourable Prognosis", <i>Thrombosis Haemost.</i> , Vol 49, pp. 5-7 (1983)   |
|  | DC | OTT et al., "Reversible Regulation of Tissue Factor-Induced Coagulation by Phosphatidylinositol-Anchored Tissue Factor Pathway Inhibitor", <i>Arterioscler. Thromb. Vasc. Biol.</i> , Vol. 20, No. 3, pp. 874-882 (March 2000).   |
|  | DD | PEDERSEN et al., "Recombinant Human extrinsic Pathway Inhibitor", <i>J. Biol. Chem.</i> , Vol. 265, pp. 16786-16793 (1990)  |
|  | DE | PETERSEN et al., "Effect of Leukocyte Proteinases on Tissue Factor Pathway Inhibitor", <i>Thrombosis and Haemostasis</i> , of F.K. Schattauer Verlagsgesellschaft mbH (Stuttgart), Vol. 67, pp. 537-541 (1992)  |
|  | DF | QUEZADO et al., "Therapies Directed Against Endotoxin-Has the Time Come?", <i>Western J. of Med.</i> , Vol. 158, pp.424-425 (1993).   |
|  | DG | RAPAPORT, "Inhibition of Factor VIIa/Tissue Factor-Induced Blood Coagulation: With Particular Emphasis Upon a Factor Xa-Dependent Inhibitory Mechanism", <i>Blood</i> , 73: 359-365 (1989).   |
|  | DH | RAPAPORT, "The Extrinsic Pathway Inhibitor: A Regulator of Tissue Factor-Dependent Thrombosis Haemost.", Vol. 66; pp. 6-15 (1991).  |
|  | DJ | REINHART, "Overview of Tifacogin Clinical Development: Brussels. Scientific Conference Blood Coagulation", (2001).  |
|  | DK | RIVERS et al., "The Endotoxin-induced Coagulant Activity of Human Monocytes", <i>Br J. Haematol.</i> , Vol. 30, pp. 311-316 (1975).   |
|  | DL | SANDSET et al., "Coagulation Inhibitor levels in Pneumonia and Stroke: Changes due to Consumption and Acute Phase Reaction" <i>J. Internal Med.</i> , Vol. 225, pp. 311-316 (1989).   |
|  | DM | SANDSET et al., "Depletion of Extrinsic Pathway Inhibitor (EPI) Sensitizes Rabbits to Disseminated Intravascular Coagulation Induced with Tissue Factor: Evidence Supporting a Physiologic Role for EPI as a Natural Anticoagulant", <i>PNAS (USA)</i> , Vol. 88, pp. 708-712 (1991). |
|  | DN | SANDSET et al., "Extrinsic Pathway Inhibitor in Postoperative/Posttraumatic Septicemia: Increased levels In Fatal Cases", <i>Haemostasis</i> , Vol. 19, pp. 189-195 (1989) (Abstract).  |

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

'FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
51752-US-PCT  
APPLICATION NO.  
10/593,135  
APPLICANT  
ABLA CREASEY  
FILING DATE  
SEPTEMBER 18, 2006

Group

EXAMINER INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

|  |        |  |
|--|--------|--|
|  | D<br>A | SANDSET et al., "Immunodepletion of Extrinsic Pathway Inhibitor Sensitizes Rabbits to Endotoxin-Induced Intravascular Coagulation and the Generalized Schwartzman Reaction", <i>Blood</i> , Vol. 78, pp. 1496-1502 (1991). |
|  | D<br>B | SANDSET et al., "Heparin Induces Release of Extrinsic Coagulation Pathway Inhibitor (EFI)", <i>Thrombosis Res.</i> , Vol. 50, pp. 808-813 (1988).  |
|  | D<br>C | SANGER et al., "DNA sequencing with chain-terminating Inhibitors", <i>PNAS (USA)</i> , Vol. 74, pp. 5463-5467 (1977).  |
|  | D<br>D | SEHGAL et al., "Heterogeneity of Poly(I).Poly(C)-Induced Human Fibroblast Interferon mRNA Species", <i>Nature</i> , Vol. 288, pp. 95-97 (1980).  |
|  | D<br>E | SHAW et al., "A General Method for the Transfer of Cloned Genes to Plant Cells", <i>Gene</i> , Vol. 23, pp. 315-330 (1983).  |
|  | D<br>F | SHIMATAKE et al., "Purified λ Regulatory Protein cII Positively Activates Promoters for Lysogenic Development", <i>Nature</i> , Vol. 292, pp. 128-132 (1981).  |
|  | D<br>G | STEPHENSON et al., "Tissue Factor Pathway Inhibitor Delays the Development of Intimal Hyperplasia in a Porcine Vein-Grafting Model", American College of Surgery, March 15, 1999, Abstract                                 |
|  | D<br>H | STINCHCOMB et al., "Isolation and Characterization of a Yeast Chromosomal Replicator", <i>Nature</i> , Vol. 262, pp. 39-43 (1979).   |
|  | D<br>J | STRAUB, "A Case Against Heparin Therapy of Intravascular Coagulation", <i>Thrombos. Diathes. Haemorrh.</i> , Vol. 33, pp. 107-112 (1974).  |
|  | D<br>K | TAYLOR et al., "DEGR-Factor Xa Blocks Disseminated Intravascular Coagulation Initiated by <i>Escherichia coli</i> Without Preventing Shock or Organ Damage", <i>Blood</i> , Vol. 78, pp. 364-368 (1991).                   |
|  | D<br>L | TAYLOR et al., "Lethal <i>E. Coli</i> Septic Shock is Prevented by Blocking Tissue Factor With Monoclonal Antibody", <i>Circulatory Shock</i> , Vol. 33, pp. 127-134 (1991).   |
|  | D<br>M | TAYLOR, "Baboon Model of <i>E. Coli</i> Sepsis: Summary of Staging, Mechanism, and Diagnostic Markers", in <i>Molecular Aspects of Inflammation</i> , 42. Colloquium Mosbach, Springer-Verlag Berlin, pp. 277-288 (1991).  |
|  | D<br>N | TSCHUMPER et al., "Sequence of a Yeast DNA Fragment Containing a Chromosomal TRP1 Gene", <i>Gene</i> , Vol. 10, pp. 157-166 (1980).  |

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

(Use several sheets if necessary)

ATTY. DOCKET NO.  
51752-US-PCT  
APPLICATION NO.  
10/593,135  
APPLICANT  
ABLA CREESEY  
FILING DATE  
SEPTEMBER 18, 2006

Group

EXAMINER  
INITIAL**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

|  |    |   |
|--|----|---|
|  | DA | VALENTIN et al., "Simultaneous Presence of Tissue Factor Pathway Inhibitor (TFPI) and Replicator end the Low Molecular Weight Heparin has a Synergistic Effect in Different Coagulation Assays", <i>Blood Coagulation Fibrinolysis</i> , Vol. 2, pp. 629-635 (1991).            |
|  | DB | VALENTIN et al., "Synergism Between Full Length TFPI and Heparin: Evidence for TFPI as an Important Factor for the Anti-thrombotic Activity of Heparin", <i>Blood Coagulation and Fibrinolysis</i> , Vol. 3, pp. 221-222 (1992).  |
|  | DC | VALLET, "Microthrombosis in Sepsis", <i>Minerva Anestesiol.</i> , Vol. 67, No. 4, pp. 298-301 (April 2001).   |
|  | DD | VAN SOLINGEN et al., "Fusion of Yeast Spheroplasts", <i>J. Bact.</i> , Vol. 130, pp. 946-947 (1977)   |
|  | DE | VAN DER POLL et al., "Dose-dependent Inhibition of Endotoxin-Induced Coagulation Activation by TFPI without Influencing the Fibrinolytic and Cytokine Response in Healthy Humans", <i>ISTH</i> (August 14, 1999).   |
|  | DF | WARR et al., "Human Plasma Extrinsic Pathway Inhibitor Activity: II. Plasma levels in Disseminated Intravascular Coagulation and Hepatocellular Disease", <i>Blood</i> , Vol. 74, pp. 994-998 (1989).   |
|  | DG | WARR et al., "Disseminated Intravascular Coagulation In Rabbits Induced by Administration of Endotoxin or Tissue Factor: Effect of Anti-Tissue Factor Antibodies and Measurement of Plasma Extrinsic Pathway Inhibitor Activity", <i>Blood</i> , Vol. 75, pp. 1481-1489 (1990). |
|  | DH | WHERRY et al., "Monoclonal Antibody to Human Tumor Necrosis Factor (TNF Mab): Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, Louisiana, Oct. 17-20, (1993)  |
|  | DJ | WUN et al., "Cloning and Characterization of a cDNA Coding for the Lipoprotein-Associated Coagulation Inhibitor Shows That It Consists of Three Tandem Kunitz-type Inhibitory Domains", <i>J. Biological Chemistry</i> , Vol. 263, pp. 6001-6004 (1988).                        |
|  | DK | WUN et al., "Immunoaffinity Purification and Characterization of Lipoprotein-Associated Coagulation Inhibitors from Hep G2 Hepatome, Chang Liver, and SK Hepatoma Cells; <i>J. Biol. Chem.</i> , Vol. 265, pp. 16096-16101 (1990).  |
|  | DL | WUN et al., "Comparison of Recombinant Tissue Factor Pathway Inhibitors Expressed in Human SK Hepatoma, Mouse C127, Ba, pp. 54-59 (1992).   |
|  | DM | YANG et al., "Comparison of Methods for Local Delivery of Tissue Factor Pathway Inhibitor to Balloon-injured Arteries in Rabbits", <i>Coron. Artery Dis.</i> , Vol. 10, No. 5, pp. 327-333 (July 1999).   |
|  | DN | ZINSSER, "The Action of Chemotherapeutic Agents", <i>MicroBiology</i> , 17th ed., W. Jokik et al., eds., pp. 235-277 (1980).  |

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
51752-US-PCT  
APPLICATION NO.  
10/593,135  
APPLICANT  
ABLA CREASEY  
FILING DATE  
SEPTEMBER 18, 2006

Group

EXAMINER  
INITIAL

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

|  |    |   |
|--|----|---|
|  | DA | Supplementary Partial European Search Report dated February 6, 2007 in the corresponding European Application No. EP 02 778 529.4 - 2107  |
|  | DB | BAJAJ et al., "Tissue Factor Pathway Inhibitor": Potential Therapeutic Applications", Thrombosis and Haemostasis, Vol. 78-7, pp. 471-477 (1997) XP009064749   |
|  | DC | SPEICH et al., "Efficacy Safety, and Tolerance of Piperacillin/Tazobactam Compared to Co-Amoxiclav plus and Aminoglycoside in the Treatment of Severe Pneumonia". European Journal of Clinical Microbiology and Infectious Diseases, Vol. 17, No. 5, pp. 313-317 (May 1998) XP002416071 |
|  | DD | KHOURI et al., "A Phase II Trial of Intraluminal irrigation with Recombinant Human Tissue Factor Pathway Inhibitor to Prevent Thrombosis in Free Flap Surgery". <i>Plast Reconstr. Surg.</i> , Vol. 107, No. 2, pp. 408-415 (2001)  |
|  | DE | POLLER et al., "Fixed Minidose Warfarin: a New Approach to Prophylaxis Against Venous Thrombosis After Major Surgery", <i>British Medical Journal (Clinical Research Edition)</i> , Vol. 295, No. 6609, pp. 1309-1312 (November 21, 1987).  |
|  | DF | OLTRONA et al., "Inhibition of tissue Factor-Mediated Coagulation Markedly Attenuates Stenosis After Balloon-Induced Arterial Injury in Minipigs", <i>Circulation</i> , Vol. 96, No. 2, pp. 646-652 (July 15, 1997).  |
|  | DG | WATERER et al., "Septic Shock and Respiratory Failure in Community-Acquired Pneumonia have Different TNF Polymorphism Associations", <i>Am. J. Respir Crit. Care Med.</i> , Vol. 163, No. 7, pp. 1599-1604 (June 2001).   |
|  | DH | RUIZ et al., "Severe Community-Acquired Pneumonia. Risk Factors and Follow-Up Epidemiology", <i>Am. J. Respir. Crit. Care Med.</i> , Vol. 160, No. 3, pp. 923-929 (Sept. 1999).   |
|  | DJ |   |
|  | DK |   |
|  | DL |   |
|  | DM |   |
|  | DN |   |

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.